Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel phosphorus-containing prodrugs

A prodrug and pharmaceutical technology, applied in the field of new phosphorus-containing prodrugs, can solve refractory liver cancer and other problems

Inactive Publication Date: 2002-06-12
METABASIS THERAPEUTICS INC
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In some cases, high renal clearance can lead to nephrotoxicity or become a major limitation in diseases such as diabetes in which renal function is often impaired
[0024] Liver cancer hard to cure with current therapies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel phosphorus-containing prodrugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0562] Example 1: General Procedure for Phosphoramidate Prodrugs of Drugs Containing Phosphonic Acids:

[0563] A suspension of 5-isobutyl-2-methyl-4-(2-(5-phosphono)furyl)thiazole (200 mg, 0.6 mmol) in 2.5 mL of thionyl chloride was heated at reflux temperature for 4 Hour. The reaction mixture was cooled and evaporated to dryness, then azeotroped with toluene. To a solution of the resulting residue in 4 ml of dichloromethane was added aminoethanol (82 mg, 0.54 mmol) and pyridine (0.5 ml, 6 mmol) in 1 mL of dichloromethane.

[0564] After stirring at 25°C for 4 hours, the reaction was evaporated and co-evaporated with toluene. The crude product was chromatographed eluting with 10% methanol-dichloromethane to afford 52 mg (20.8%) of the less polar isomer and 48 mg (19.2%) of the more polar isomer.

[0565] The following compound was prepared in this way: 1.1: 5-isobutyl-2-methyl-4-{2-[5-(1-phenyl-1,3-propyl)phosphonimino]furyl}thiazole , the less polar isomer. Rf = 0.76 in...

Embodiment 2

[0566] Embodiment 2: Step A:

[0567] At 0°C, a solution of 3-amino-3-phenyl-1-propanol (1 g, 6.6 mmol) and triethylamine (3 ml, 21.8 mmol) in tetrahydrofuran (60 ml) was added dropwise to 4-Nitrophenyl dichlorophosphate in solution in tetrahydrofuran. A white precipitate formed rapidly. The yellow heterogeneous mixture was stirred at 0 °C for 1 h, then slowly warmed to room temperature. After stirring at room temperature for 60 hours, the precipitate was dissolved in water (40ml). The clear yellow solution was concentrated to about 40ml. The resulting mixture was diluted with saturated aqueous sodium bicarbonate and extracted twice with ethyl acetate. The combined organic extracts were washed with saturated aqueous sodium bicarbonate and brine. The aqueous washes were extracted again and the organic extracts were combined. The combined organic extracts were dried over sodium sulfate, concentrated and purified by column chromatography (silica gel, hexane / ethyl acetate) t...

Embodiment 3

[0570] Embodiment 3: Step A:

[0571] Same as step A of embodiment 2. Step B:

[0572] Lithium hydride (15 mg, 1.52 mmol) was added to 9-β-D-arabinofurano-adenine (100 mg, 0.37 mmol) and the rapidly eluting (4-nitrophenoxy)-4- Phenyl-1,3,2-oxazaphosphorin-2-one (250 mg, 0.74 mmol) in solution in dimethylformamide. After 6 hours, the yellow heterogeneous mixture was neutralized with acetic acid. The clear yellow solution was concentrated and the residue was purified by column chromatography (silica gel, methanol / dichloromethane). The isolated product was further purified by preparative TLC and recrystallized from ethanol to afford the prodrug: 18 mg (11% yield).

[0573] The following compound was prepared in this way: 3.15'-O-(2-oxo-4-phenyl-1,3,2-oxazaphosphorin-2-yl)-9-β-D-A Sugar Furanadenine. mp>250. Rf = 0.25 (silica gel, 2 / 8 methanol / dichloromethane). C 19 h 23 N 6 o 6 Theoretical values ​​of P: C: 49.35; H: 5.01; N: 18.17. Found values: C: 49.22; H: 4.89; N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel cyclic phosphoramidate prodrugs of drugs of formula (I), their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

Description

[0001] related application [0002] This application is a continuation-in-part of Provisional Application Serial No. 60 / 153127 (filed September 8, 1999) and Provisional Application Serial No. 60 / 123013 (filed March 5, 1999), which are hereby incorporated by reference. field of invention [0003] The present invention relates to novel prodrugs which generate phosphonate compounds which are biologically active or which are further phosphorylated to produce biologically active compounds, to their preparation, to their synthetic intermediates and to their use. More specifically, the present invention relates to substituted cyclic 1,3-propyl esters wherein the ring moiety contains at least one amino group attached to phosphorus. Background of the invention [0004] The following description of the background of the invention is provided to aid in understanding the present invention and is not considered to be prior art to, or describes prior art to, the present invention. All pu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07F9/6584
CPCC07F9/65848C07F9/65846A61P1/16A61P3/04A61P31/12A61P33/00A61P33/06A61P35/00A61P3/06A61P43/00A61P7/04A61P9/10A61P3/10
Inventor M·D·埃里安K·R·雷迪S·H·波耶尔
Owner METABASIS THERAPEUTICS INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More